Myocardial protective effect of human atrial natriuretic peptide in cardiac surgery: "hANP shot" in clinical safety trial

Circulation Journal

Volumn 75, Issue 9, 2011, Pages 2144-2150

  Sezai, Akira ^a   Wakui, Shinji ^a   Akiyama, Kenji ^a   Hata, Mitsumasa ^a   Yoshitake, Isamu ^a   Unosawa, Satoshi ^a   Shiono, Motomi ^a   Hirayama, Atsushi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atrial natriuretic peptide; Coronary artery bypass grafts surgery; Natriuretic peptides

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE MB; CYCLIC GMP; FATTY ACID BINDING PROTEIN; PLACEBO; RENIN; TROPONIN I;

AGED; ARTICLE; BOLUS INJECTION; BRAIN INFARCTION; CARDIOPLEGIA; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART SURGERY; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; SURGICAL MORTALITY;

AGED; ALDOSTERONE; ANGIOTENSIN II; ARRHYTHMIAS, CARDIAC; ATRIAL NATRIURETIC FACTOR; CARDIOTONIC AGENTS; CORONARY ARTERY BYPASS; CREATINE KINASE, MB FORM; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACID-BINDING PROTEINS; FEMALE; HEART ARREST, INDUCED; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; POSTOPERATIVE COMPLICATIONS; RENIN; TROPONIN I;

EID: 80052158403     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0185     Document Type: Article

References (28)

1. Kangawa K, Matsuo H. Purification and complete amino acid sequence of α-human atrial natriuretic polypeptide (α-hANP). Biochem Biophys Res Commun 1984; 120: 333-338.
2. Asanuma H, Kitakaze M. Carperitide and adiponectin: How are they connected each other to benefit acute decompensated heart failure? Circ J 2009; 73: 2206-2207.
3. Saito Y, Nakao K, Nishimura K, Sugawara A, Okumura K, Obata K, et al. Clinical application of atrial natriuretic polypeptide in patients with congestive heart failure: Beneficial effects of left ventricular function. Circulation 1987; 76: 115-124.
4. Hayashi M, Tsutamoto T, Wada A, Maeda K, Mabuchi N, Tsutui T, et al. Intravenous atrial natriuretic peptide prevents left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2001; 37: 1820-1826.
5. Kasama S, Furuya M, Toyama T, Ichikawa S, Kurabayashi M. Effect of atrial natriuretic peptide on left ventricular remodeling in patients with acute myocardial infarction. Eur Heart J 2008; 29: 1485-1494.
6. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, et al. Evaluation of cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. J Am Coll Cardiol 2007; 49: 667-674.
7. Nishikimi T, Karasawa T, Inaba C, Ishimura K, Tadokoro K, Koshikawa S, et al. Effects of long-term intravenous administration of adrenomedullin (AM) plus hANP therapy in acute decompensated heart failure: A pilot study. Circ J 2009; 73: 892-898.
8. Inserte J, Garcia-Dorado D, Agullo L, Paniagua A, Soler-Soler J. Urodilatin limits acute reperfusion injury in the isolated rat heart. Cardiovasc Res 2000; 45: 351-359.
9. Sagawa K, Nakanishi K, Ishino K, Inoue M, Kawada M, Sano S. Atrial natriuretic peptide protects against ischemia-reperfusion injury in the isolated rat heart. Ann Thorac Surg 2004; 77: 223-227.
10. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): Two randomized trials. Lancet 2007; 370: 1483-1493.
11. Sezai A, Shiono M, Orime Y, Hata H, Hata M, Negishi N, et al. Lowdose continuous infusion of human atrial natriuretic peptide during and after cardiac surgery. Ann Thorac Surg 2000; 69: 732-738.
12. Sezai A, Hata M, Wakui S, Shiono M, Negishi N, Kasamaki Y, et al. Efficacy of low-dose continuous infusion of alpha-human atrial natriuretic peptide (hANP) during cardiac surgery: Possibility of postoperative left ventricular remodeling effect. Circ J 2006; 70: 1426-1431.
13. Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, et al. Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery: A randomized controlled study. J Am Coll Cardiol 2009; 54: 1058-1064.
14. Sezai A, Hata M, Niino T, Yoshitake I, Unosawa S, Wakui S, et al. Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: The NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery) for left ventricular dysfunction. J Am Coll Cardiol 2010; 55: 1844-1851.
15. Wakui S. Experimental study on myocardial protection by adjunct use of carperitide (hANP) in cardiac surgery. Ann Thorac Cardiovasc Surg 2005; 11: 12-20.
16. Wakui S, Sezai A, Tenderich G, Hata M, Osaka S, Taniguchi Y, et al. Experimental investigation of direct myocardial protective effect of atrial natriuretic peptide in cardiac surgery. J Thorac Cardiovasc Surg 2010; 139: 918-925.
17. Tsukamoto S, Shiono M, Orime Y, Hata H, Yagi S, Yamamoto T, et al. Appropriate intervals of multidose cardioplegia and risk factors for myocardial protection. Coronary 1999; 16: 65-69 (in Japanese).
18. Domanski MJ, Mahaffey K, Hasselblad V, Brener SJ, Smith PK, Hillis G, et al. Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA 2011; 305: 585-591.
19. Hayashida N, Chihara S, Kashikie H, Tayama E, Yokose S, Akasu K, et al. Effects of intraoperative administration of atrial natriuretic peptide. Ann Thorac Surg 2000; 70: 1319-1326.
20. Swärd K, Valsson F, Odencrants P, Samuelsson O, Ricksten SE. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: A randomized placebo-controlled trial. Crit Care Med 2004; 32: 1310-1315.
21. Mentzer RM, Oz MC, Sladen RN, Graeve AH, Hebeler RF, Luber JM, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardia surgery. J Am Coll Cardiol 2007; 49: 716-726.
22. Chen HH, Sundt TM, Cook DJ, Heublein DM, Burnett JC. Low dose nesiritide and the preservation of renal function in patients with renal dysfunction undergoing cardiopulmonary-bypass surgery: A doubleblind placebo-controlled pilot study. Circulation 2007; 116: I134-I138.
23. Lazar HL, Bao Y, Siwik D, Frame J, San Mateo C, Wilson S, et al. Nesiritide enhances myocardial protection during the revascularization of acutely ischemic myocardium. J Card Surg 2009; 24: 600-605.
24. Kimura K, Yamaguchi Y, Horii M, Kawata H, Yamamoto H, Uemura S, et al. ANP is cleared much faster than BNP in patients with congestive heart failure. Eur J Clin Pharmacol 2007; 63: 699-702.
25. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005; 111: 1487-1491.
26. Ishihara T, Aisaka K, Hattori K, Hamasaki S, Morita M, Noguchi T, et al. Vasodilatory and diuretic actions of α-human atrial natriuretic peptide (α-hANP). Life Sci 1985; 36: 1205-1215.
27. Brady AJB, Warren JB, Poole-Wilson PA, Williams TJ, Harding SE. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol 1993; 265: H176-H182.
28. Weiss HR, Rodriguez E, Tse J, Scholz PM. Effect of increased myocardial cyclic GMP induced by cyclic GMP-phosphodiesterase inhibition on oxygen consumption and supply of rabbit hearts. Clin Exp Pharmacol Physiol 1994; 21: 607-614.